This trial is active, not recruiting.

Condition intestinal amebiasis
Sponsor Pfizer
Start date October 2015
End date September 2019
Trial size 200 participants
Trial identifier NCT02680665, B3391001


This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Number of Paticipants With Adverse Events (AEs) by Seriousness and Relationship to Treatment
time frame: Maximum 10 days

Secondary Outcomes

Number of Participants With Clinical Response of Cure
time frame: Maximum 3 months

Eligibility Criteria

All participants from 15 years up to 99 years old.

Inclusion Criteria: - Patients with no history of using this product Exclusion Criteria: - No exclusion criteria are set out in this study.

Additional Information

Official title Drug Use Investigation Of Paromomycin. (Regulatory Post Marketing Commitment Plan).
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Pfizer.